Novara-T™

Personalized Cancer Support System

Novara-T™ is an advanced precision oncology support solution designed for confirmed cancer cases where personalized immune-recognition planning may be required.

Cancer cells are not always easily recognized by the immune system. Over time, they may develop ways to hide, change their surface signals, or reduce immune visibility. This can make it harder for the body’s natural defense system to identify abnormal cells effectively.

Novara-T™ is developed around a personalized tumor-intelligence concept. It focuses on using patient-specific tumor-associated biological information to support immune recognition, allowing a more tailored and targeted oncology support strategy.

This makes Novara-T™ suitable for patients who require a more individualized immune-focused approach as part of doctor-led cancer management.

WHAT NOVARA-T™ IS?

Novara-T™ is a personalized tumor antigen intelligence platform.

It is designed to support the immune system by introducing selected tumor-associated biological information derived from the patient’s own cancer profile.

In cancer biology, tumor cells may carry unique signatures that differentiate them from normal healthy cells. These signatures may include tumor-related surface patterns, structural components, protein fragments, cellular signals, and other biological markers linked to abnormal cancer-cell behavior.

Novara-T™ is designed to help create a clearer immune reference profile so the body’s defense system can better recognize tumor-associated signals.

In simple terms:

Novara-T™ helps the immune system better understand what it needs to recognize.

HOW NOVARA-T™ WORKS?

The process begins with a patient-specific cancer-cell and immune assessment.

Through advanced profiling, the patient’s tumor-associated biological information is reviewed. This helps identify relevant antigenic patterns and immune-related signals that may be useful for personalized planning.

Once the patient’s cancer profile and immune readiness are assessed, Novara-T™ is prepared as a personalized immune-recognition support product.

The goal is to provide the immune system with a more specific tumor-associated reference, helping support immune awareness and recognition.

Instead of only asking:

“What type of cancer does the patient have?”

Novara-T™ goes further and asks:

“What unique tumor signals does this patient’s immune system need to recognize?”

WHAT MAKES NOVARA-T™ DIFFERENT?

• Personalized to Each Patient
  • Novara-T™ is developed based on the patient’s own tumor-associated biological profile. It is not a standard, one-size-fits-all product.
• Tumor-Antigen Intelligence
  • It focuses on tumor-associated recognition signals rather than general immune stimulation.
• Immune Recognition Support
  • Novara-T™ is designed to support the immune system’s ability to identify cancer-related biological patterns more clearly.
• Non-Live-Cell Concept
  • Novara-T™ is not a live-cell infusion product. It is not NK cell therapy and not CAR-T therapy. It works through a tumor-antigen intelligence concept that supports immune recognition.
• Designed for Precision Oncology
  • Novara-T™ supports a more individualized oncology strategy by combining cancer-cell information with immune-status review.
• Supports Doctor-Led Planning
  • Novara-T™ is intended to be used as part of a professional oncology support plan, under the supervision of qualified healthcare personnel.

KEY BENEFITS

• Supports Personalized Immune Recognition
  • Helps provide tumor-associated information that may support immune awareness.
• Guides Immune-Focused Oncology Planning
  • Useful when doctors want to explore whether immune-recognition support is suitable for the patient.
• Uses Patient-Specific Tumor Intelligence
  • Developed based on the patient’s own cancer-related biological profile.
• Complements Advanced Cancer-Cell Profiling
  • Can be considered alongside blood-based cancer-cell assessment and immune-status profiling.
• Supports a More Targeted Support Strategy
  • Helps move beyond generic immune support toward a more personalized, data-guided approach.

WHO NOVARA-T™ IS DESIGNED FOR?

Novara-T™ is designed for confirmed cancer patients who may require personalized immune-recognition support as part of a professional oncology plan.

It may be considered for patients who:

• have a confirmed cancer diagnosis
• require deeper cancer-cell profiling before planning
• are exploring personalized oncology support
• may benefit from immune-recognition assessment
• require doctor-led immune-focused planning
• are undergoing advanced cancer management review
• need a more individualized strategy beyond general wellness care

Suitability depends on professional review of:

• cancer type
• disease stage
• tumor burden
• immune status
• current treatment status
• blood-based cancer-cell findings
• imaging results
• medical history
• organ function
• overall clinical condition

Novara-T™ may not be suitable for every patient, especially where immune function is severely compromised. A professional medical review is required before use.

RECOMMENDED PRE-ASSESSMENT

Before Novara-T™ can be considered, patients should undergo appropriate professional evaluation to assess:

• cancer-cell profile
• tumor-associated biological signals
• immune activation or suppression status
• current treatment history
• suitability for immune-recognition support

This helps ensure that Novara-T™ is used only when the patient’s condition and immune status are suitable.

IMPORTANT NOTICE

Novara-T™ is intended for professional and doctor-supervised use only. It is not chemotherapy, radiation therapy, NK cell therapy, or CAR-T therapy. It is not intended to diagnose, treat, cure, or prevent any disease as a standalone product.

Suitability must be determined by qualified medical professionals based on the patient’s clinical condition, cancer profile, immune status, investigation results, and overall treatment plan.